ROCK-IN-32 | CAS#1013117-40-2 | ROCK inhibitor

MedKoo Cat#: 562877 | Name: ROCK-IN-32

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ROCK-IN-32 is a potent Rho--kinase (ROCK) inhibitor.

Chemical Structure

ROCK-IN-32

CAS#1013117-40-2

Theoretical Analysis

MedKoo Cat#: 562877

Name: ROCK-IN-32

CAS#: 1013117-40-2

Chemical Formula: C20H17Cl2N3O2

Exact Mass: 401.0698

Molecular Weight: 402.27

Elemental Analysis: C, 59.72; H, 4.26; Cl, 17.62; N, 10.45; O, 7.95

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

ROCK-IN-32; ROCK IN 32; ROCKIN32; ROCK-inhibitor-32; ROCK inhibitor 32;

IUPAC/Chemical Name

trans--4-(4-Chlorophenyl)pyrrolidine-3-carboxylic acid N-(7-chloro-1-oxo-1,2-dihydroisoquinolin-6-yl)amide

InChi Key

XBFAFSAUQFDEOK-CVEARBPZSA-N

InChi Code

InChI=1S/C20H17Cl2N3O2/c21-13-3-1-11(2-4-13)15-9-23-10-16(15)20(27)25-18-7-12-5-6-24-19(26)14(12)8-17(18)22/h1-8,15-16,23H,9-10H2,(H,24,26)(H,25,27)/t15-,16+/m1/s1

SMILES Code

ClC1=CC=C([C@H]2CNC[C@@H]2C(NC3=CC4=C(C(NC=C4)=O)C=C3Cl)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 402.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhou ZY, Huang B, Li S, Huang XH, Tang JY, Kwan YW, Hoi PM, Lee SM. Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish. Toxicol Appl Pharmacol. 2018 May 4;350:32-42. doi: 10.1016/j.taap.2018.04.037. [Epub ahead of print] PubMed PMID: 29730311. 2: Ni Y, Qin Y, Fang Z, Zhang Z. ROCK Inhibitor Y-27632 Promotes Human Retinal Pigment Epithelium Survival by Altering Cellular Biomechanical Properties. Curr Mol Med. 2017;17(9):637-646. doi: 10.2174/1566524018666180316150936. PubMed PMID: 29546834. 3: White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. PubMed PMID: 29527974. 4: Rubinstein PG, Moore PC, Rudek MA, Henry DH, Ramos JC, Ratner L, Reid E, Sharon E, Noy A; AIDS Malignancy Consortium (AMC). Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. AIDS. 2018 Mar 13;32(5):605-611. doi: 10.1097/QAD.0000000000001729. PubMed PMID: 29280762; PubMed Central PMCID: PMC5832596. 5: Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 2018 Feb;32(2):391-401. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5. PubMed PMID: 28676669; PubMed Central PMCID: PMC5808083. 6: Takahashi C, Kurano M, Nishikawa M, Kano K, Dohi T, Miyauchi K, Daida H, Shimizu T, Aoki J, Yatomi Y. Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression. J Atheroscler Thromb. 2017 Sep 1;24(9):954-969. doi: 10.5551/jat.37663. Epub 2017 Mar 17. PubMed PMID: 28321011; PubMed Central PMCID: PMC5587522. 7: Chen J, Yin W, Tu Y, Wang S, Yang X, Chen Q, Zhang X, Han Y, Pi R. L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-κB inhibition and Nrf2 pathway activation. Eur J Pharmacol. 2017 Jul 5;806:1-9. doi: 10.1016/j.ejphar.2017.03.025. Epub 2017 Mar 16. PubMed PMID: 28320516. 8: Chen J, Sun Z, Jin M, Tu Y, Wang S, Yang X, Chen Q, Zhang X, Han Y, Pi R. Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway. J Neuroimmunol. 2017 Apr 15;305:108-114. doi: 10.1016/j.jneuroim.2017.02.010. Epub 2017 Feb 8. PubMed PMID: 28284330. 9: Ghasemi A, Hashemy SI, Aghaei M, Panjehpour M. RhoA/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells. Cell Signal. 2017 Apr;32:104-114. doi: 10.1016/j.cellsig.2017.01.020. Epub 2017 Jan 16. PubMed PMID: 28104444. 10: Yang Q, Crispino JD, Wen QJ. Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol. 2017 Apr;48:32-38. doi: 10.1016/j.exphem.2016.12.007. Epub 2016 Dec 30. Review. PubMed PMID: 28043820; PubMed Central PMCID: PMC5362340. 11: Dai ZK, Kao CL, Hsieh SL, Chen IJ, Wu BN. Restoration of uridine 5'-triphosphate-suppressed delayed rectifying K(+) currents by an NO activator KMUP-1 involves RhoA/Rho kinase signaling in pulmonary artery smooth muscle cells. Kaohsiung J Med Sci. 2016 Dec;32(12):607-613. doi: 10.1016/j.kjms.2016.09.008. Epub 2016 Oct 27. PubMed PMID: 27914611. 12: Isobe T, Kasai T, Kawai H. Ocular Penetration and Pharmacokinetics of Ripasudil Following Topical Administration to Rabbits. J Ocul Pharmacol Ther. 2016 Sep;32(7):405-14. doi: 10.1089/jop.2016.0028. Epub 2016 Jul 27. PubMed PMID: 27463221. 13: Gao QQ, Chen H, Chen Y, Xu ZP, Zhu LL, Yu W, Han YF, Dai YT. [Effects of the Rho-kinase inhibitor fasudil on the invasion, migration, and apoptosis of human prostate cancer PC3 and DU145 cells]. Zhonghua Nan Ke Xue. 2016 Jun;22(6):483-490. Chinese. PubMed PMID: 28963834. 14: Liu CP, Yeh JL, Liou SF, Wu BN, Chen IJ. Phosphodiesterase inhibitor KMUP-3 displays cardioprotection via protein kinase G and increases cardiac output via G-protein-coupled receptor agonist activity and Ca(2+) sensitization. Kaohsiung J Med Sci. 2016 Feb;32(2):55-67. doi: 10.1016/j.kjms.2016.01.005. Epub 2016 Feb 24. PubMed PMID: 26944323. 15: Duess JW, Puri P, Thompson J. Impaired cytoskeletal arrangements and failure of ventral body wall closure in chick embryos treated with rock inhibitor (Y-27632). Pediatr Surg Int. 2016 Jan;32(1):45-58. doi: 10.1007/s00383-015-3811-z. Epub 2015 Nov 13. PubMed PMID: 26563157. 16: Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015 May;35(5):281-9. doi: 10.1007/s40261-015-0279-5. PubMed PMID: 25896946; PubMed Central PMCID: PMC4544506. 17: Hara H, Tagiri M, Hirabayashi M, Hochi S. Multiple aster formation is frequently observed in bovine oocytes retrieved from 1-day stored ovaries. Zygote. 2016 Feb;24(1):115-20. doi: 10.1017/S096719941400080X. Epub 2015 Mar 3. PubMed PMID: 25732862. 18: Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother. 2014;10(9):2638-47. doi: 10.4161/hv.29707. Epub 2014 Nov 1. PubMed PMID: 25483484; PubMed Central PMCID: PMC4852362. 19: Chen W, Mao K, Hua-Huy T, Bei Y, Liu Z, Dinh-Xuan AT. Fasudil inhibits prostate cancer-induced angiogenesis in vitro. Oncol Rep. 2014 Dec;32(6):2795-802. doi: 10.3892/or.2014.3491. Epub 2014 Sep 17. PubMed PMID: 25333508. 20: Grisk O, Koenen A, Meissner T, Donner A, Braun D, Steinbach A, Glöckl G, Zimmermann U, Evert K, Evert M, Katsari E, Löhn M, Plettenburg O, Rettig R. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption. J Hypertens. 2014 Nov;32(11):2199-210; discussion 2110. doi: 10.1097/HJH.0000000000000326. PubMed PMID: 25275248.